Zealand Pharma Weighs Petrelintide Progress Against Sharp Share Price Reset

• Zealand Pharma reported positive Phase 2 topline results for petrelintide, its obesity drug candidate, with clinically meaningful weight loss and strong tolerability.
• The trial met its primary weight reduction endpoint and showed a favorable safety profile, according to the company.
• The news has arrived as investors reassess Zealand Pharma’s position in the obesity drug space and its collaboration with Roche.

For holders of CPSE:ZEAL, the latest petrelintide data lands after a sharp reset in the share price. The stock last closed at DKK234.9, with a 35.4% decline over 7 days, a 45.4% decline over 30 days, and a 48.9% decline year to date. Over a 5-year period, the share price shows a 22.6% gain, highlighting how recent trading has contrasted with the longer-term picture.

Looking ahead, investors will likely focus on how Zealand Pharma and Roche shape the Phase 3 plan for petrelintide and clarify where the drug could fit in obesity treatment. The key questions now center on trial design, potential combination approaches, and how the company positions its broader pipeline around this program.

Stay updated on the most important news stories for Zealand Pharma by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Zealand Pharma.

We’ve flagged 2 risks for Zealand Pharma. See which could impact your investment.

Quick Assessment

• ✅ Price vs Analyst Target: At DKK234.9 versus an average analyst target of DKK682.21, the share price sits around 66% below consensus expectations.
• ❌ Simply Wall St Valuation: DCF valuation is currently marked as unknown, so you do not have a clear Fair Value cross check here.
• ❌ Recent Momentum: A 45.4% decline over 30 days shows very weak short term sentiment around the stock.

There is only one way to know the right time to buy, sell or hold Zealand Pharma. Head to Simply Wall St’s
company report for the latest analysis of Zealand Pharma’s Fair Value.

Key Considerations

• 📊 The petrelintide readout confirms clinically meaningful weight loss and tolerability, but falling short of analyst expectations keeps questions open on how competitive this asset could be in obesity care.
• 📊 Keep an eye on how Phase 3 design, any Roche collaboration updates, and the relatively low P/E of 2.6x versus a Danish market P/E of 16.4x may shape sentiment from here.
• ⚠️ Analysts currently forecast earnings to decline by an average of 84.7% per year over the next 3 years, which heightens the importance of pipeline execution and funding discipline.

Dig Deeper

For the full picture including more risks and rewards, check out the
complete Zealand Pharma analysis. Alternatively, you can check out the
community page for Zealand Pharma to see how other investors believe this latest news will impact the company’s narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com